|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
12230 El Camino Real, Suite 300, San Diego, California 92130, US
|
|
Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression.
The pipeline includes cirmtuzumab, a monoclonal antibody in Phase 1/2 development that inhibits the ROR1 receptor in various hematologic cancers; TK-216, a small-molecule in Phase 1 development that inhibits ETS-family oncoproteins, as a treatment for Ewing sarcoma, a rare pediatric cancer; and a CAR-T therapy that targets ROR1 currently in preclinical development as a potential treatment for solid tumors and hematologic cancers.
Based in San Diego, Oncternal is committed to advancing its pipeline rapidly and efficiently to bring patients a new wave of first-in-class cancer treatments.
|
Oncternal Therapeutics Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75%
|
The widely used Oncternal Therapeutics email format is {f}{last} (e.g. [email protected]) with 75% adoption across the company.
To contact Oncternal Therapeutics customer service number call here (858) 434-1113. To contact Oncternal Therapeutics customer service number in your country click here to find.
Jim Breitmeyer is the CEO of Oncternal Therapeutics. To contact Jim Breitmeyer email at [email protected], [email protected] or [email protected]. Or you may call 8587597540
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.